Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLFS NASDAQ:ESTA NASDAQ:MDXG NASDAQ:SMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.46+2.3%$23.10$19.10▼$29.55$1.27B1.78583,602 shs314,440 shsESTAEstablishment Labs$39.03+0.9%$41.41$26.56▼$50.85$1.13B0.85392,709 shs173,812 shsMDXGMiMedx Group$7.14+0.7%$6.90$5.47▼$10.14$1.06B1.74458,070 shs366,086 shsSMTISanara MedTech$33.57-1.4%$29.06$23.53▼$39.08$298.85M1.1938,759 shs11,747 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+2.28%+5.63%+25.46%+11.60%+7.21%ESTAEstablishment Labs+0.93%-5.43%-6.60%+2.71%-6.60%MDXGMiMedx Group+0.71%+0.56%-1.38%+10.02%+8.51%SMTISanara MedTech-1.38%-0.27%+36.74%+13.84%-2.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLFSBioLife Solutions$26.46+2.3%$23.10$19.10▼$29.55$1.27B1.78583,602 shs314,440 shsESTAEstablishment Labs$39.03+0.9%$41.41$26.56▼$50.85$1.13B0.85392,709 shs173,812 shsMDXGMiMedx Group$7.14+0.7%$6.90$5.47▼$10.14$1.06B1.74458,070 shs366,086 shsSMTISanara MedTech$33.57-1.4%$29.06$23.53▼$39.08$298.85M1.1938,759 shs11,747 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLFSBioLife Solutions+2.28%+5.63%+25.46%+11.60%+7.21%ESTAEstablishment Labs+0.93%-5.43%-6.60%+2.71%-6.60%MDXGMiMedx Group+0.71%+0.56%-1.38%+10.02%+8.51%SMTISanara MedTech-1.38%-0.27%+36.74%+13.84%-2.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLFSBioLife Solutions 3.13Buy$31.2918.24% UpsideESTAEstablishment Labs 2.83Moderate Buy$56.5044.76% UpsideMDXGMiMedx Group 3.00Buy$12.0068.07% UpsideSMTISanara MedTech 3.00Buy$50.0048.94% UpsideCurrent Analyst Ratings BreakdownLatest SMTI, BLFS, ESTA, and MDXG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025ESTAEstablishment LabsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/18/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $54.008/18/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $54.008/11/2025BLFSBioLife SolutionsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/8/2025BLFSBioLife SolutionsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00 ➝ $32.007/31/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$11.00 ➝ $12.007/22/2025BLFSBioLife SolutionsStephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$30.007/16/2025ESTAEstablishment LabsMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $70.007/15/2025MDXGMiMedx GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$11.007/9/2025ESTAEstablishment LabsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$38.00 ➝ $47.006/13/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$48.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLFSBioLife Solutions$82.25M15.41$0.12 per share215.98$7.52 per share3.52ESTAEstablishment Labs$166.02M6.81N/AN/A$1.90 per share20.54MDXGMiMedx Group$348.88M3.03$0.33 per share21.55$1.31 per share5.45SMTISanara MedTech$86.67M3.45N/AN/A$4.45 per share7.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLFSBioLife Solutions-$20.18M-$0.12N/AN/AN/A-5.39%0.16%0.14%11/11/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.05N/AN/AN/A-49.89%-224.34%-25.53%11/6/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2134.0022.31N/A8.84%23.03%17.09%10/29/2025 (Estimated)SMTISanara MedTech-$9.66M-$1.16N/AN/AN/A-10.22%-26.43%-10.69%11/11/2025 (Estimated)Latest SMTI, BLFS, ESTA, and MDXG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SMTISanara MedTech-$0.33-$0.23+$0.10-$0.23$25.15 million$25.83 million8/7/2025Q2 2025BLFSBioLife Solutions-$0.02-$0.33-$0.31-$0.33$23.71 million$25.42 million8/7/2025Q2 2025ESTAEstablishment Labs-$0.54-$0.57-$0.03-$0.57$50.80 million$51.30 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLFSBioLife SolutionsN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLFSBioLife SolutionsN/A4.433.45ESTAEstablishment Labs9.712.841.67MDXGMiMedx Group0.084.393.90SMTISanara MedTech1.252.262.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLFSBioLife Solutions93.24%ESTAEstablishment Labs72.91%MDXGMiMedx Group79.15%SMTISanara MedTech8.10%Insider OwnershipCompanyInsider OwnershipBLFSBioLife Solutions2.20%ESTAEstablishment Labs11.09%MDXGMiMedx Group1.70%SMTISanara MedTech42.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLFSBioLife Solutions44047.90 million46.85 millionOptionableESTAEstablishment Labs1,01828.97 million25.76 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionableSMTISanara MedTech608.90 million5.11 millionNot OptionableSMTI, BLFS, ESTA, and MDXG HeadlinesRecent News About These CompaniesSanara MedTech: Growth Remains Strong As Debt Concerns RecedeSeptember 4 at 3:04 PM | seekingalpha.comSanara MedTech stock falls after CEO succession announcementSeptember 3 at 7:23 PM | za.investing.comSanara MedTech Shares Dip Following CEO Succession AnnouncementSeptember 3 at 7:23 PM | msn.comSeth Yon Named CEO of Sanara MedTech Inc., Ron Nixon to Remain Executive ChairmanSeptember 2, 2025 | quiverquant.comQSanara MedTech Inc. Announces Chief Executive Officer TransitionSeptember 2, 2025 | globenewswire.comAnalysts Expect Breakeven For Sanara MedTech Inc. (NASDAQ:SMTI) Before LongSeptember 1, 2025 | finance.yahoo.comSanara MedTech Inc. to Present at the Cantor Global Healthcare Conference on September 3, 2025August 27, 2025 | globenewswire.comSanara Medtech Inc News (SMTI) - Investing.comAugust 23, 2025 | investing.comQ3 EPS Estimates for Sanara MedTech Boosted by HC WainwrightAugust 22, 2025 | marketbeat.comHC Wainwright Forecasts Sanara MedTech Q1 EarningsAugust 21, 2025 | marketbeat.comFY2025 EPS Estimate for Sanara MedTech Raised by AnalystAugust 19, 2025 | marketbeat.comSanara MedTech price target raised to $54 from $53 at H.C. WainwrightAugust 18, 2025 | msn.comSanara MedTech (NASDAQ:SMTI) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPSAugust 16, 2025 | marketbeat.comSanara MedTech Reports Strong Revenue Growth in Q2 2025August 14, 2025 | msn.comSanara MedTech Inc. (NASDAQ:SMTI) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | msn.comSanara MedTech Inc. (SMTI) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comSanara MedTech Sales Jump 28 PercentAugust 13, 2025 | theglobeandmail.comSanara MedTech Inc. (SMTI) Reports Q2 Loss, Tops Revenue EstimatesAugust 13, 2025 | zacks.comSanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited)August 13, 2025 | globenewswire.comSanara MedTech Inc (SMTI) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 12, 2025 | finance.yahoo.comSanara MedTech (NASDAQ:SMTI) investors are sitting on a loss of 12% if they invested three years agoAugust 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Restaurant Stocks That Will Outperform in Q3 and Q4By Thomas Hughes | August 15, 2025With Rate Cuts Ahead, Buffett-Backed Builders Look Like a BuyBy Jordan Chussler | September 4, 20253 Stocks Poised to Gain from a September Rate CutBy Chris Markoch | September 4, 2025SMTI, BLFS, ESTA, and MDXG Company DescriptionsBioLife Solutions NASDAQ:BLFS$26.46 +0.59 (+2.28%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$26.46 +0.00 (+0.02%) As of 09/5/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.Establishment Labs NASDAQ:ESTA$39.03 +0.36 (+0.93%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$39.02 -0.01 (-0.03%) As of 09/5/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.MiMedx Group NASDAQ:MDXG$7.14 +0.05 (+0.71%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.14 0.00 (0.00%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Sanara MedTech NASDAQ:SMTI$33.57 -0.47 (-1.38%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$33.57 0.00 (0.00%) As of 09/5/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
